{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:44:01Z","timestamp":1780109041531,"version":"3.54.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Heart failure (HF) significantly affects the morbidity, mortality, and quality of life of patients. New therapeutic strategies aim to improve the functional capacity and quality of life of patients while controlling HF-related risks. Real-world data on both the functional and cardiopulmonary exercise capacities of patients with HF with reduced ejection fraction upon sacubitril\/valsartan use are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicenter, retrospective, cohort study, called REAL.IT, was performed based on the data collected from the electronic medical records of nine specialized HF centers in Italy. Cardiopulmonary exercise testing was performed at baseline and after 12 months of sacubitril\/valsartan therapy, monitoring carbon dioxide production (VCO<jats:sub>2<\/jats:sub>) and oxygen consumption (VO<jats:sub>2<\/jats:sub>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The functional capacities of 170 patients were evaluated. The most common comorbidities were hypertension and diabetes (i.e., 53.5 and 32.4%, respectively). At follow-up, both the VO<jats:sub>2<\/jats:sub> peak (from 15.1\u2009\u00b1\u20093.7\u2005ml\/kg\/min at baseline to 17.6\u2009\u00b1\u20094.7\u2005ml\/kg\/min at follow-up, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001) and the predicted % VO<jats:sub>2<\/jats:sub> peak (from 55.5\u2009\u00b1\u200914.1 to 65.5\u2009\u00b1\u200916.9, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001) significantly increased from baseline. The VO<jats:sub>2<\/jats:sub> at the anaerobic threshold (AT-VO<jats:sub>2<\/jats:sub>) increased from 11.5\u2009\u00b1\u20092.6 to 12.5\u2009\u00b1\u20093.3\u2005ml\/kg\/min (<jats:italic>p<\/jats:italic>\u2009=\u20090.021), and the rate ratio between the oxygen uptake and the change in work (\u0394VO<jats:sub>2<\/jats:sub>\/\u0394work slope) improved from 9.1\u2009\u00b1\u20091.5 to 9.9\u2009\u00b1\u20091.6\u2005ml\/min\/W (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Sacubitril\/valsartan improves the cardiopulmonary capacity of patients with HFrEF in daily clinical practice in Italy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1347908","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:10:33Z","timestamp":1715317833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of sacubitril\/valsartan on the functional capacity of real-world patients in Italy: the REAL.IT study on heart failure with reduced ejection fraction"],"prefix":"10.3389","volume":"11","author":[{"given":"Filippo Maria","family":"Sarullo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Nugara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sarullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iacoviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Di Gesaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Miani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Driussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Passantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erberto","family":"Carluccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Lenarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40292-017-0193-4","article-title":"The burden of chronic heart failure in primary care in Italy","volume":"24","author":"Piccinni","year":"2017","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e07","DOI":"10.15420\/cfr.2022.13","article-title":"Effects of sacubitril\/valsartan on exercise capacity in patients with heart failure with reduced ejection fraction and the role of percentage of delayed enhancement measured by cardiac magnetic resonance in predicting therapeutic response","volume":"8","author":"Nugara","year":"2023","journal-title":"Card Fail Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"882","DOI":"10.2459\/JCM.0000000000001018","article-title":"Sacubitril\/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction","volume":"21","author":"Mapelli","year":"2020","journal-title":"J Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3390\/jcm12020699","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction: real-world experience from Italy (the REAL.IT study)","volume":"12","author":"Di Lenarda","year":"2023","journal-title":"J Clin Med"},{"key":"B11","author":"Iacoviello","year":""},{"key":"B12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1071-9164(05)80009-0","article-title":"Evaluation of the dead space\/tidal volume ratio in patients with chronic congestive heart failure","volume":"1","author":"Guazzi","year":"1995","journal-title":"J Card Fail"},{"key":"B13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/VHRM.S114784","article-title":"Profile of sacubitril\/valsartan in the treatment of heart failure: patient selection and perspectives","volume":"13","author":"Yandrapalli","year":"2017","journal-title":"Vasc Health Risk Manag"},{"key":"B14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","article-title":"Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review","volume":"331","author":"Proudfoot","year":"2021","journal-title":"Int J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ejhf.979","article-title":"Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Corr\u00e0","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.apmr.2016.08.481","article-title":"Association between 6-min walk test distance and objective variables of functional capacity after exercise training in elderly heart failure patients with preserved ejection fraction: a randomized exercise trial","volume":"98","author":"Maldonado-Martin","year":"2017","journal-title":"Arch Phys Med Rehabil"},{"key":"B17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ahj.2003.07.014","article-title":"Peak VO2 and VE\/VCO2 slope in patients with heart failure: a prognostic comparison","volume":"147","author":"Arena","year":"2004","journal-title":"Am Heart J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1053\/euhj.1999.1863","article-title":"Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE\/VCO(2)slope and peak VO(2)","volume":"21","author":"Francis","year":"2000","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ijcard.2006.07.105","article-title":"Prognostic value of the VE\/VCO2 slope calculated from different time intervals in patients with suspected heart failure","volume":"118","author":"Ingle","year":"2007","journal-title":"Int J Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11897-017-0330-3","article-title":"Six-minute walk test for assessing physical functional capacity in chronic heart failure","volume":"14","author":"Du","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"505969","DOI":"10.1155\/2014\/505969","article-title":"The long-term prognostic significance of 6-min walk test distance in patients with chronic heart failure","volume":"2014","author":"Ingle","year":"2014","journal-title":"Biomed Res Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.cardfail.2016.01.012","article-title":"The added value of exercise variables in heart failure prognosis","volume":"22","author":"Alba","year":"2016","journal-title":"J Card Fail"},{"key":"B23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.recesp.2017.11.019","article-title":"Early sacubitril\/valsartan-driven benefit on exercise capacity in heart failure with reduced ejection fraction: a pilot study","volume":"72","author":"Palau","year":"2019","journal-title":"Rev Esp Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/jcm8020262","article-title":"Early effects of sacubitril\/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction","volume":"8","author":"Vitale","year":"2019","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/ehf2.12338","article-title":"Sacubitril-valsartan in heart failure and multimorbidity patients","volume":"5","author":"Rodil Fraile","year":"2018","journal-title":"ESC Heart Fail"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000484879","article-title":"Sacubitril\/valsartan: effect on walking test and physical capability","volume":"138","author":"Sgorbini","year":"2017","journal-title":"Cardiology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijcard.2017.10.074","article-title":"Sacubitril\/valsartan and short-term changes in the 6-min walk test: a pilot study","volume":"252","author":"Beltr\u00e1n","year":"2018","journal-title":"Int J Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1080\/00015385.2019.1669317","article-title":"Improvement of functional capacity in sacubitril\u2013valsartan treated patients assessed by cardiopulmonary exercise test","volume":"75","author":"Malfatto","year":"2020","journal-title":"Acta Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00228-023-03527-y","article-title":"Effects of sacubitril\/valsartan on exercise capacity: a prognostic improvement that starts during uptitration","volume":"79","author":"Mapelli","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"971108","DOI":"10.3389\/fcvm.2022.971108","article-title":"Impact of sacubitril\/valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: hemodynamic or pleiotropism?","volume":"9","author":"Mapelli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40268-023-00438-2","article-title":"Looking into the kinetics of NT-proBNP and sST2 changes in patients with heart failure treated with sacubitril\/valsartan: a hint to different therapeutic pathways","volume":"23","author":"Mapelli","year":"2023","journal-title":"Drugs R D"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/diagnostics11101845","article-title":"Cardiac reverse remodelling by 2D and 3D echocardiography in heart failure patients treated with sacubitril\/valsartan","volume":"11","author":"Mantegazza","year":"2021","journal-title":"Diagnostics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/biomedicines11041037","article-title":"Impact of sacubitril\/valsartan on circulating microRNA in patients with heart failure","volume":"11","author":"Brioschi","year":"2023","journal-title":"Biomedicines"},{"key":"B34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ehf2.12610","article-title":"Sacubitril\/valsartan in patients listed for heart transplantation: effect on physical frailty","volume":"7","author":"Cacciatore","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1152\/japplphysiol.00454.2020","article-title":"Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction","volume":"130","author":"Bunsawat","year":"2021","journal-title":"J Appl Physiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.17219\/acem\/128230","article-title":"Sacubitril\/valsartan for heart failure with reduced ejection fraction: a first real-life observational study in Poland","volume":"30","author":"Lelonek","year":"2021","journal-title":"Adv Clin Exp Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"555","DOI":"10.23736\/S2724-5683.20.05494-8","article-title":"Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril\/valsartan: a real-life experience","volume":"70","author":"Dattilo","year":"2022","journal-title":"Minerva Cardiol Angiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1347908\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:10:35Z","timestamp":1715317835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1347908\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":37,"alternative-id":["10.3389\/fcvm.2024.1347908"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1347908","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"article-number":"1347908"}}